HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PHOTODYNAMIC THERAPY FOR SYMPTOMATIC SUBFOVEAL RETINAL PIGMENT EPITHELIAL DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: Outcomes and Prognostic Factors.

AbstractPURPOSE:
To report the clinical outcomes of reduced-fluence photodynamic therapy (PDT) for symptomatic subfoveal retinal pigment epithelial detachment (RPED) in central serous chorioretinopathy and identify prognostic factors affecting treatment outcome.
METHODS:
This retrospective interventional study included 35 eyes of 35 patients with serous subfoveal RPED with choroidal hyperpermeability. Cases with evidence of age-related macular degeneration were excluded from the study. Reduced-fluence PDT was applied to each patient. Best-corrected visual acuity, anatomical resolution of RPED, subjective symptom improvement, and complications were analyzed.
RESULTS:
One month after reduced-fluence PDT, 28 eyes (80.0%) manifested complete resolution of subfoveal RPED. Among the patients whose eyes manifested complete resolution, 19 (67.9%) reported subjective vision improvement. This subjective improvement was significantly associated with the presence of dysmorphopsia at baseline. Logarithm of the minimal angle of resolution visual acuity improved from 0.15 (Snellen equivalent of 20/28) to 0.09 (20/25) between baseline and 3 months after PDT (P = 0.008). Older age and increased RPED height were independent risk factors of poor resolution of RPED after PDT. The mean follow-up period after treatment was 10.4 ± 13.6 months; recurrence of RPED did not occur in any case.
CONCLUSION:
Subfoveal RPED in central serous chorioretinopathy responded well to reduced-fluence PDT, especially in younger patients with less RPED. Dysmorphopsia, rather than decreased visual acuity, is a main symptomatic presentation in subfoveal RPED.
AuthorsSungsoon Hwang, Se Woong Kang, Sang Jin Kim, Jun Won Jang, Kyung Tae Kim
JournalRetina (Philadelphia, Pa.) (Retina) Vol. 39 Issue 6 Pg. 1117-1124 (Jun 2019) ISSN: 1539-2864 [Electronic] United States
PMID29517581 (Publication Type: Journal Article)
Chemical References
  • Photosensitizing Agents
  • Verteporfin
Topics
  • Central Serous Chorioretinopathy (complications, diagnosis, drug therapy)
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fovea Centralis (pathology)
  • Fundus Oculi
  • Humans
  • Male
  • Middle Aged
  • Photochemotherapy (methods)
  • Photosensitizing Agents (therapeutic use)
  • Prognosis
  • Retinal Detachment (diagnosis, drug therapy, etiology)
  • Retinal Pigment Epithelium (pathology)
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Verteporfin (therapeutic use)
  • Visual Acuity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: